Jonathan D. Cheng - Researcher Profile

Publications

2 shown

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Tanguy Y. Seiwert , Barbara Burtness , Ranee Mehra +9 more

2016 The Lancet Oncology 1684 citations

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda , Laura Q.M. Chow , Elizabeth Claire Dees +9 more

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...

2016 Journal of Clinical Oncology 1427 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 3,111
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

External Links

Google Scholar

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.